In Dec 2018, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®). Chiome will continue research and clinical development for Tb535H. In addition, Chiome will also continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed.
Biotecnol Limited, a spin-off of Biotecnol SA, a Portuguese pioneering company with a 20 year track record in development of Biologics, is an immuno-oncology company developing immune-function activating and immuno function modulation approaches using multi-specific antibody products based on its proprietary Tribody™ and Trisoma® technologies.
Biotecnol has devised a novel way to further expand on the Tribody™ format and the Trisoma® platform to generate novel IP on a next generation of immune-response modulators called – Targeted T-cell Engaging Agonistic Response Modifiers or iChecks™. These products aim at improving tumor cell dependent T-cell activation. Due to its trispecific nature, the approach is expected to achieving a more localized immune activation and obtain less or no systemic toxicity with an increased therapeutic index. These are potentially safer and more effective drugs for highly-heterogeneous and highly-aggressive solid tumours.
In 2017 the Cancer Research UK became shareholder in Biotecnol; Clinical research in oncology has evolved significantly over the last 5 years. Novel protocols using combination therapies of a variety of novel biological and traditional chemical agents have shown great promise in managing survival in cancer patients. Biotecnol’s strategy is to work with top cancer institutions in the immune-oncology field, such as CRUK, which will help the company to accelerate the development of cutting-edge therapeutic approaches to fight cancer, especially in solid tumours, an area which is in great demand for effective products.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Lbic Building, 2 Royal College Street,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- biotecnol.com
- Keywords
- Recombinant Antibodies, T cell engaging, Multispecific Antibodies, Oncology, immuno-oncology.
- HQ
- London
Biotecnol Limited Questions
Biotecnol Limited's website is biotecnol.com
Biotecnol Limited's LinkedIn profile is https://uk.linkedin.com/company/biotecnol
Biotecnol Limited has
13 employees.
View email and phone details for 13
employees at Biotecnol Limited.
Biotecnol Limited's industry is
Biotechnology Research
Biotecnol Limited's top competitors are
Edp,
Biotrend Sa,
Generis Farmacêutica,
Hovione,
Isogenica,
Rodon Biologics,
Cellmabs,
Bosch Portugal,
Genibet Biopharmaceuticals,
Biosckin, Molecular And Cell Therapies S.a..
Biotecnol Limited's categories are Biotechnology Research
Biotecnol Limited's founding year is 2014
